Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40520-018-0983-0 | DOI Listing |
Aging Clin Exp Res
March 2019
Section of Geriatrics, Department of Medicine, University of Verona, Verona, Italy.
Cochrane Database Syst Rev
February 2015
Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK, EH8 9AG.
Background: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors influence occlusion rates in these patients, including the material used.
View Article and Find Full Text PDFJ Contemp Dent Pract
November 2014
Professor, Department of Oral and Maxillofacial Surgical and Medical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.
Oral submucous fibrosis is a chronic, progressive scarring disease associated with both significant morbidity including pain and limited mouth opening and an increased risk for malignancy. This systematic review evaluated the different medicinal (i.e.
View Article and Find Full Text PDFCardiol Rev
June 2009
Department of Cardiology, The Dan Sheingarten Echocardiography Unit and Valvular Clinic, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.
Chest
September 2004
Division of Vascular Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-9157, USA.
This chapter about antithrombotic therapy for peripheral arterial occlusive disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs, and Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004;126:179S-187S). Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!